In 2012, the top 10% (T10) of psoriasis patients accounted for nearly 40% of overall healthcare expenditures among enrollees with psoriasis in a US health plan, a recent study found. Researchers conducted a retrospective study of patients with psoriasis with continuous enrollment in a plan from January 1, 2011, to December 31, 2013. Demographics, comorbidities, prescriptions, all-cause, and psoriasis-related healthcare utilization and costs were compared between cohorts. 18,653 patients (mean age 48 years; 49% female) were included. They found:
- Patients in the T10 group accounted for 26% (2011), 39% (2012) and 26% (2013) of all-cause costs including biologics and 13% (2011), 18% (2012) and 11% (2013) of psoriasis-related costs.
- Mean 2012 total costs were $58,030 for T10 vs. $10,295 for B90 (all-cause) and $10,475 vs $5,301 (psoriasis-related).
- T10 patients in 2012 filled more prescriptions and were more likely to use corticosteroids (57% vs 31%); however, biologic use and costs were similar (any use: 23% vs 24%; prescriptions: 1.5 vs 1.7, biologic costs: $4,959 vs $5,095).
Armstrong AW, Zhao Y, Herrera V, et al. Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan. [Published online ahead of print March 20, 2017]. J Dermatolog Treat. doi:10.1080/09546634.2017.1303566.Full Article